1 in 63 Before 45. The Black Man's Cardiovascular Inheritance.

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL NPI: 1831684125 | Born in Nairobi, Kenya | Trained in medicine in Kenya and the United States

I write this paper as a Black cardiologist who trained in Kenya and practices in the United States. I am not at a clinical or cultural remove from the subject. The men described in this paper look like me. Some of them are my patients. Some of them are people I know.

I write this because the cardiovascular data for Black men in the United States is urgent and the clinical response to it is not commensurate with the urgency.

The Numbers

One in 63 Black men in the United States dies of cardiac causes before age 45. 5 / Solid This was documented in a 2025 analysis in the American Journal of Preventive Cardiology examining premature cardiovascular mortality by race and sex from 2011 to 2021. (Rivera-Hernandez et al. 2025, Am J Prev Cardiol)

For context: the equivalent rate in white men under 45 is approximately one in 200.

Between 2000 and 2022, there were 779,387 excess cardiovascular deaths among Black Americans compared to white Americans at the same age-adjusted rates. (JACC 2024) 5 / Solid These are not statistical abstractions. They are people who were alive and should not have died from cardiovascular disease at those ages.

What Drives the Gap: The Biological Component

Salt-Sensitive Hypertension

Black Americans have a higher prevalence of salt-sensitive hypertension than any other demographic group in the United States. This is a physiological reality with a documented genetic and evolutionary basis.

Salt sensitivity refers to the degree to which blood pressure responds to variations in sodium intake. In populations with ancestral exposure to hot climates and variable water access, efficient sodium retention was adaptive. On the high-sodium American diet, that efficiency becomes a vulnerability: blood pressure rises more steeply with sodium intake than in individuals without this pattern.

The clinical consequence is hypertension that begins earlier, reaches higher absolute levels, and has more severe target organ effects at equivalent ages than hypertension in white patients. Black men have the highest prevalence of hypertension of any demographic group in the United States, and the highest rates of hypertension-related complications including heart failure, stroke, and renal disease. 5 / Solid

Pharmacogenomic Differences in Treatment Response

The response to antihypertensive drug classes differs between Black and white patients in ways that are clinically important and frequently not accounted for in treatment decisions.

ACE inhibitors and angiotensin receptor blockers are less effective as first-line monotherapy in Black patients with hypertension compared to white patients. The mechanism is related to differences in renin-angiotensin system activity: the average Black hypertensive patient tends to have lower renin levels and a volume-mediated hypertension pattern that responds less to RAAS blockade.

Calcium channel blockers and thiazide diuretics are more effective as first-line agents in this population. This is documented in the ALLHAT trial, the largest antihypertensive outcomes trial conducted in the United States, which specifically examined outcomes by race. 5 / Solid (ALLHAT Officers, JAMA 2002)

The clinical implication: a Black man with hypertension being treated with ACE inhibitor monotherapy without blood pressure control is not simply in a “monitor and adjust” situation. He is potentially in a situation where the choice of drug class is working against the pathophysiology.

What Drives the Gap: The Structural Component

Biology does not explain the full magnitude of the disparity. When researchers control for traditional cardiovascular risk factors, socioeconomic position, and access to care, the residual biological contribution narrows substantially. What remains includes structural factors with documented biological expression.

Allostatic Load and the Weathering Hypothesis

Dr. Arline Geronimus at the University of Michigan developed the weathering hypothesis from her analysis of differential health trajectories between Black and white Americans across the life course. The hypothesis: Black Americans experience accelerated biological aging relative to white Americans at equivalent ages due to the chronic stress of navigating a society that generates specific, sustained psychosocial stressors for Black citizens. 4 / Promising

This weathering is documented in biomarkers: allostatic load indices, telomere length, epigenetic aging clocks, and cortisol patterns all show evidence of accelerated biological aging in Black Americans that is independent of income, education, and lifestyle factors. The effect is present in middle-class and affluent Black Americans, not only those experiencing poverty.

The mechanism: chronic perceived discrimination, hypervigilance in environments that communicate racial threat, and the sustained cognitive and emotional load of performing while managing racial stress produce a sympathetic nervous system activation pattern that mimics, at a lower intensity, the biological signature of chronic threat. This produces real HPA dysregulation, real inflammatory cytokine production, and real cardiovascular consequences.

Access Disparities in Preventive Care

Black men are less likely to have a primary care physician relationship. They are less likely to have received statin therapy at equivalent measured risk levels as white men. They are less likely to receive referrals to cardiology specialists at comparable symptom presentations. These are documented in peer-reviewed analyses of health insurance claims data, electronic health records, and physician prescribing patterns.

The result: the man who is already carrying the highest cardiovascular risk is the man most likely to encounter the clinical system late, to receive less aggressive preventive therapy when he does, and to have his risk underestimated by standard risk calculators that were validated in populations that did not fully represent him.

The Family History Signal

A strong family history of premature cardiovascular disease changes every risk calculation. For Black men specifically, where premature cardiovascular events are substantially more common than in white men, the family history signal is both more likely to be present and more likely to be clinically significant.

A Black man with a father or brother who had a cardiac event before 55 has a family history that, when combined with the population-level data, creates a compelling case for preventive cardiology evaluation well before the standard age of recommendation.

The Clinical Urgency

The standard annual physical designed for a middle-aged American man was designed around a population that was not primarily Black. The risk tools were validated in cohorts that underrepresented Black men. The treatment algorithms reflect pharmacogenomic data that was not always derived from relevant populations.

The cardiovascular encounter that serves Black men well requires:

Explicit blood pressure management targeted to below 130/80 with drug class selection accounting for the predominant hypertension phenotype.

ApoB measurement, because the atherogenic lipid pattern associated with insulin resistance and metabolic syndrome is disproportionately prevalent and underdiagnosed.

Earlier preventive cardiology engagement. The window of highest clinical impact is earlier in this population than in white men.

Explicit acknowledgment of allostatic load as a cardiovascular risk factor. The question “what are you carrying that the standard visit does not have time to ask about?” is a clinical question with cardiovascular relevance for every patient, and its answer may be particularly important for Black male patients.

Heart Failure and Sudden Cardiac Death: The Less-Discussed Statistics

The mortality statistics cited above are dominated by coronary artery disease, but a second mechanism accounts for a substantial share of early cardiovascular death in Black men: heart failure with reduced ejection fraction (HFrEF) driven by hypertensive cardiomyopathy, and the arrhythmic deaths that follow from it.

The sequence is well characterized. Uncontrolled hypertension, sustained over years, imposes a chronic pressure burden on the left ventricle. The ventricle responds by thickening its walls, a process called left ventricular hypertrophy (LVH). LVH is initially compensatory. Over time, the structural change produces diastolic dysfunction, meaning the thickened muscle becomes stiff and fills poorly between beats. If the pressure load continues, the ventricle dilates and systolic function declines, which is the transition to HFrEF. Ejection fraction below 35% defines a heart that is now pumping less than a third of its blood volume with each beat.

The MESA study (Multi-Ethnic Study of Atherosclerosis), a prospective cohort that enrolled over 6,000 participants across six U.S. cities, documented that Black participants had significantly higher rates of LV hypertrophy and lower LV ejection fraction at baseline compared to white participants, after adjusting for traditional risk factors. 5 / Solid The structural damage was present before a cardiac event, in people who had not yet been diagnosed with heart failure.

The arrhythmic consequence of LVH and myocardial fibrosis is equally important. Fibrosis creates electrical heterogeneity in the myocardium, meaning signals travel unevenly through scar tissue and normal muscle. That heterogeneity is the substrate for ventricular arrhythmias. This is the mechanism behind sudden cardiac death: not a blocked coronary artery in the immediate moment, but a ventricle that has been electrically remodeled by years of pressure overload and is now prone to fatal rhythm disturbances. Black men have higher rates of sudden cardiac death compared to white men, a disparity that reflects this upstream structural and electrical remodeling. The time to intervene is before the LVH is established, which means controlling blood pressure now, at target, with the right drug class.

The REGARDS Study and Stroke Risk

Stroke is the cardiovascular outcome most directly and mechanically linked to blood pressure, and the racial disparity in stroke incidence is among the most clearly documented in the literature.

The REGARDS study (Reasons for Geographic And Racial Differences in Stroke) enrolled 30,239 Americans aged 45 and older and followed them prospectively to examine stroke incidence and mortality by race and geography. 5 / Solid (Howard et al., Neuroepidemiology 2005) The study found that Black Americans had approximately twice the stroke incidence of white Americans during the first decade of follow-up. The excess was not distributed evenly: Black men in the “stroke belt” states, specifically Alabama, Arkansas, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, and Tennessee, carried particularly elevated risk compared to Black men in other regions and white men nationwide.

The mechanism underlying this excess is predominantly hypertensive. Hemorrhagic stroke, caused by a ruptured blood vessel under sustained pressure, and lacunar infarct, a small vessel occlusion produced by hypertensive damage to the penetrating arteries of the brain, together account for the disproportionate stroke burden in the Black population. These are not the same mechanism as large-vessel atherosclerotic stroke. They are, in the most direct sense, blood pressure diseases. The vessel walls that fail under hemorrhagic stroke were weakened by years of elevated pressure. The small vessels that occlude in lacunar infarct were remodeled and narrowed by the same sustained load.

This matters because it is the most preventable form of cerebrovascular disease. Achieving sustained blood pressure control below 130/80 reduces stroke risk by approximately 40 percent. That is a large and reproducible effect. The data is not ambiguous on this point. A Black man in a stroke belt state, with hypertension not at target, is carrying a risk that has a specific and modifiable cause.

What Distrust of the Healthcare System Costs, Biologically

The U.S. medical system has accumulated a documented record with Black Americans that makes distrust a rational response, not a failure of health literacy. The Tuskegee Syphilis Study is the most widely cited example, but it is not the only one. Forced sterilization programs, J. Marion Sims’s experimental surgeries on enslaved women without anesthesia, and decades of documented racial bias in pain assessment and treatment decisions are part of the same institutional history. That history is not ancient. Physicians practicing today trained in systems built on those foundations.

The man who avoids the cardiologist because he does not expect to be heard, does not expect his symptoms to be taken at face value, and does not expect his questions to be answered without condescension is not being irrational. He is making a calculation based on documented experience, his own and his community’s. That calculation has a cardiovascular cost, measured in delayed presentations, missed early interventions, and untreated hypertension that remodels the heart and the brain over years.

This section does not ask him to trust the system. It gives him specific information to use the system more aggressively on his own terms, reducing his dependence on physician initiative.

What to ask for by name, in writing, at every visit: blood pressure target below 130/80 documented in the clinical note; drug class rationale if on antihypertensive therapy without reaching target; ApoB measured, not just LDL; fasting glucose and hemoglobin A1c; and, if there is any family history of early cardiac events, a referral to preventive cardiology with that history stated explicitly. These are not unusual requests. They are standard of care. The point of naming them is to remove the asymmetry between physician initiative and patient outcome.

Knowing what questions to ask, and insisting on documented answers, shifts the clinical encounter. It is not a substitute for a system that should function without requiring this level of self-advocacy. But it is the position of power that exists now, for the man who is in the system now.

Three Actions

1. Know your blood pressure. At home, consistently, over multiple readings. Target below 130/80. If you are on antihypertensive therapy without achieving that target, ask your physician whether your drug class is appropriate for your likely hypertension phenotype.

2. Establish care with a primary care physician before something requires it. The access gap closes one appointment at a time. This week, not next quarter.

3. Tell your physician your family history explicitly: who had a cardiac event, and when. That history changes your risk calculation in ways the standard visit may not surface unless you name it.

This paper is educational and does not constitute medical advice. Discuss your individual clinical situation with your physician.